Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit against Humana, Inc.

Coughlin Stoia Geller Rudman & Robbins LLP ("Coughlin Stoia”) (http://www.csgrr.com/cases/humana/) today announced that a class action has been commenced in the United States District Court for the Western District of Kentucky on behalf of purchasers of Humana, Inc. ("Humana” or the "Company”) (NYSE:HUM) common stock during the period between February 4, 2008 and March 11, 2008 (the "Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than 60 days from today. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Samuel H. Rudman or David A. Rosenfeld of Coughlin Stoia at 800/449-4900 or 619/231-1058, or via e-mail at djr@csgrr.com. If you are a member of this class, you can view a copy of the complaint as filed or join this class action online at http://www.csgrr.com/cases/humana/. Any member of the purported class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. The complaint charges Humana and certain of its officers and directors with violations of the Securities Exchange Act of 1934. The Company provides various health and supplemental benefit plans for employer groups, government benefit programs, and individuals in the United States. According to the complaint, during the Class Period, defendants issued materially false and misleading statements concerning the Company’s anticipated earnings per share ("EPS”) for the first quarter of 2008 and full year 2008. As alleged in the complaint, these statements were materially false misleading because defendants failed to disclose: (i) that the Company was unable to properly calculate the prescription drug costs of its newly acquired members; (ii) that the Company’s costs associated with its prescription drug plans had dramatically increased; and (iii) that as a result of the foregoing, defendants’ statements concerning the Company’s anticipated EPS for the first quarter of 2008 and full year 2008 were lacking in a reasonable basis at all relevant times and were therefore materially false and misleading. On March 12, 2008, the Company announced that it would be revising its earnings estimates because of, among other things, increased costs that it was experiencing with the Company’s prescription drug plans. Following this announcement, shares of Humana stock fell $6.50 per share, or approximately 13.7%, to close at $40.88 per share. Plaintiff seeks to recover damages on behalf of all purchasers of Humana common stock during the Class Period (the "Class”). The plaintiff is represented by Coughlin Stoia, which has expertise in prosecuting investor class actions and extensive experience in actions involving financial fraud. Coughlin Stoia, a 190-lawyer firm with offices in San Diego, San Francisco, Los Angeles, New York, Boca Raton, Washington, D.C., Philadelphia and Atlanta, is active in major litigations pending in federal and state courts throughout the United States and has taken a leading role in many important actions on behalf of defrauded investors, consumers, and companies, as well as victims of human rights violations. The Coughlin Stoia Web site (http://www.csgrr.com) has more information about the firm.